Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (2,591,790)	$ (4,291,483)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		5,167
Amortization of debt discounts related to convertible notes payable	8,378
Loss on extinguishment of debt	105,254
Loss on extinguishment of other liabilities	11,154
Loss on exchange of officer note	49,974
Stock-based compensation and fees included in - General and administrative expenses	14,248	1,164,537
Stock-based compensation and fees included in - Research and development expenses	15,000	762,741
Foreign currency transaction loss (gain)	112,641	(58,153)
(Increase) decrease in -
Prepaid expenses	18,962	26,772
Increase (decrease) in -
Accounts payable and accrued expenses	703,682	476,449
Accrued compensation and related expenses	1,025,484	1,117,439
Accrued interest payable	99,645	99,522
Net cash used in operating activities	(427,368)	(697,009)
Cash flows from financing activities:
Proceeds from sale of common stock units and issuance of restricted stock, net of fees	195,750	754,500
Proceeds from officer notes	100,000
Proceeds from issuance of notes payable	80,000
Principal paid on other short-term notes payable		(64,629)
Net cash provided by financing activities	375,750	689,871
Cash and cash equivalents:
Net decrease	(51,618)	(7,138)
Balance at beginning of period	84,902	92,040
Balance at end of period	33,284	84,902
Cash paid for -
Interest	3,345	2,608
Non-cash financing activities:
10% convertible notes payable, including accrued interest of $62,267, exchanged for common stock	213,266
Accounts payable and accrued expenses extinguished with common stock options	138,273
Accrued compensation extinguished with option to purchase common stock options	200,350
Officer note payable, exchanged for common stock and warrants	50,000
Short-term note payable issued in connection with financing of directors and officers insurance policy	63,750	59,857
Short-term note payable issued in connection with financing of clinical trial and other office insurance policies	9,322	9,307
Fair value of common stock issued to service provider	198,550
Accrual of fees payable to placement agent in connection with the sale common stock units		20,000
Fair value of common stock warrants issued to placement agent in connection with the sale of common stock units		27,648
Reclassification of non-permanent equity		$ 185,000